13F Holdings
中文EN

CLDX Celldex Therapeutics, Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 744218 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-93.9%
TTM net income YoY-37.6%
TTM EPS YoY-26.9%
Revenue 3-yr CAGR-66.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-211,684.8%
Net margin-195,608.9%
FCF margin-164,391.8%
EBITDA margin-209,321.5%

Returns

ROE-49.5%
ROA-45.1%
ROIC (approx.)-44.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue4,915.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$1.54M$7.02M$6.88M$2.36M$4.65M
Cost of revenue$200,000$200,000$300,000$100,000$100,000
Gross profit$1.34M$6.82M$6.58M$2.26M$4.55M
R&D expense$245.07M$163.55M$118.01M$82.26M$53.31M
SG&A expense$43.84M$38.55M$30.91M$27.20M$20.49M
Operating income-$287.37M-$195.08M-$154.54M-$115.23M-$71.24M
Pretax income-$258.76M-$157.86M-$141.43M-$112.33M-$70.74M
Income tax$0$0$0—-$227,000
Net income-$258.76M-$157.86M-$141.43M-$112.33M-$70.51M
EBITDA-$283.99M-$191.90M-$151.53M-$112.34M-$68.17M
EPS (basic)-3.90-2.45-2.92-2.40-1.64
EPS (diluted)-3.90-2.45-2.92-2.40-1.64
Weighted avg. shares (diluted)66.42M64.39M48.45M46,88842,870
Balance sheet
Cash & equivalents$28.87M$28.36M$34.81M$29.43M$39.14M
Short-term investments$489.70M$696.92M$388.78M$275.52M$369.11M
Current assets$534.66M$747.16M$431.69M$317.69M$410.84M
PP&E, net$5.33M$4.35M$4.06M$3.75M$3.55M
Intangibles$27.19M$27.19M$27.19M$27.19M$27.19M
Total assets$582.98M$792.34M$465.63M$352.74M$444.65M
Current liabilities$50.99M$39.50M$31.12M$18.61M$16.53M
Total liabilities$55.82M$45.34M$36.46M$26.53M$25.18M
Shareholders' equity$527.16M$747.00M$429.17M$326.20M$419.48M
Shares outstanding66.55M66.37M55.88M47.20M46.73M
Cash flow statement
Operating cash flow-$210.94M-$157.78M-$107.29M-$103.73M-$60.91M
Capital expenditure$2.71M$1.92M$1.82M$1.83M$1.25M
Free cash flow-$213.66M-$159.70M-$109.11M-$105.56M-$62.16M
Investing cash flow$209.07M-$290.13M-$105.78M$89.94M-$216.16M
Financing cash flow$2.39M$441.45M$218.46M$4.08M$272.37M
Depreciation & amortization$3.38M$3.18M$3.01M$2.90M$3.07M
Stock-based compensation$36.22M$34.24M$23.89M$15.61M$8.95M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.